Genetic Counselling — Symptoms, Causes & Treatment | MyMedicPlus

Genetic counselling is a specialised communication and educational process provided by trained healthcare professionals — genetic counsellors, clinical geneticists, or nurse specialists in genetics — to individuals, couples, or families who are concerned about the inheritance, diagnosis, management, or implications of genetic conditions within their family. The process integrates genetic risk assessment, education about inheritance patterns, psychological support, and facilitation of informed decision-making regarding reproductive choices, diagnostic testing, preventive surveillance, and medical management. The World Health Organization (WHO) defines genetic counselling as 'the process by which patients or relatives at risk of a disorder that may be hereditary are advised of the consequences of the disorder, the probability of developing and transmitting it, and the ways in which this may be prevented or ameliorated.' Genetic counselling is non-directive — the professional role is to provide accurate information and support autonomous decision-making without imposing personal values or directing patients toward specific choices. The scope of genetic counselling has expanded dramatically with advances in genomic medicine: next-generation sequencing (NGS), chromosomal microarray analysis, whole exome sequencing (WES), whole genome sequencing (WGS), and liquid biopsy-based prenatal genetic testing now generate vast amounts of genetic information requiring expert interpretation and communication. Genetic counsellors are increasingly embedded across specialties — oncology, cardiology, neurology, obstetrics, paediatrics, and reproductive medicine — reflecting the growing integration of precision medicine into mainstream clinical care.

Genetic counselling is indicated across a broad and expanding spectrum of clinical scenarios. Pre-conception counselling: blood-related (consanguineous) couples — who have elevated shared allele risk; individuals or couples from ethnic groups with high carrier frequencies for specific autosomal recessive disorders (e.g., Ashkenazi Jewish populations for Tay-Sachs disease, Gaucher disease, Canavan disease, Niemann-Pick disease type A; Mediterranean, Middle Eastern, and South Asian populations for thalassaemia; Afro-Caribbean populations for sickle cell disease); individuals with a personal or family history of a hereditary condition; carriers of chromosomal rearrangements (balanced translocations — increased risk of unbalanced offspring). Prenatal genetic counselling: advanced maternal age (above 35 years — elevated risk of trisomies, particularly Down syndrome trisomy 21); abnormal cell-free DNA non-invasive prenatal testing (NIPT) result; abnormal prenatal ultrasound findings (structural anomalies, echogenic bowel, choroid plexus cysts, nuchal translucency above 3.5 mm); previous pregnancy affected by a chromosomal abnormality or genetic condition. Paediatric referrals: developmental delay, intellectual disability, autism spectrum disorder (ASD), multiple congenital anomalies, dysmorphic features, or suspected inherited metabolic disorder. Adult-onset hereditary disorders: BRCA1/BRCA2 hereditary breast and ovarian cancer; Lynch syndrome (hereditary non-polyposis colorectal cancer — HNPCC); familial hypercholesterolaemia; hypertrophic cardiomyopathy (MYBPC3, MYH7 mutations); inherited arrhythmia syndromes (long QT syndrome — KCNQ1, KCNH2, SCN5A; Brugada syndrome); hereditary haemochromatosis; Wilson disease; neurological disorders (Huntington's disease; familial ALS; spinocerebellar ataxias).

Genetic counselling is itself a healthcare service rather than a disease, but a wide range of clinical presentations and life circumstances prompt referral. Dysmorphic features in a child (unusual facial features such as wide-set eyes — hypertelorism, low-set ears, unusual palmar creases, short stature) may indicate a chromosomal syndrome or single-gene disorder requiring genetic diagnosis for management, recurrence risk counselling, and prognosis. Developmental delay, intellectual disability (IQ below 70), autism spectrum disorder, or learning difficulties — particularly when combined with dysmorphic features — warrant genetic evaluation as chromosomal causes (chromosomal microarray — detects copy number variants in 15–20% of cases of unexplained intellectual disability) or single-gene mutations are identified in approximately 30–50% of cases with comprehensive testing. Positive cancer predisposition gene testing: identification of a pathogenic BRCA1/2, TP53, PALB2, ATM, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM mutation requires cascade family testing, personalised cancer surveillance (enhanced MRI mammography, colonoscopy, prophylactic surgery considerations), and chemoprevention planning. Recurrent pregnancy loss (two or more consecutive miscarriages — present in 2–3% of couples): chromosomal analysis of products of conception detects chromosomal causes in 50–60% of first-trimester losses; parental karyotyping identifies balanced translocations in 5% of couples with recurrent miscarriage. Family history of hereditary cardiac conditions: sudden cardiac death in a young relative (below 40 years), hypertrophic cardiomyopathy, channelopathies, or dilated cardiomyopathy — cascade genetic testing may identify at-risk relatives who can be protected with medication, ICD implantation, or lifestyle modification before a potentially fatal cardiac event.

A structured and comprehensive genetic assessment includes multiple complementary tools: Three-generation pedigree construction: a detailed family history spanning at least three generations — documenting affected relatives, their specific diagnoses, ages of onset, ages of death and causes, consanguinity, and ethnic background — allows identification of inheritance patterns (autosomal dominant, autosomal recessive, X-linked, mitochondrial, multifactorial) and calculation of empiric recurrence risks. Genetic testing modalities range from specific focused tests to genome-wide analyses: Chromosomal microarray analysis (CMA/SNP array): detects copy number variants (CNVs — deletions and duplications of chromosomal segments too small for conventional karyotype) with far higher resolution than standard karyotype; first-line investigation for unexplained developmental delay, multiple congenital anomalies, and autism (diagnostic yield 15–20% vs 3–5% for karyotype); also detects uniparental disomy and regions of homozygosity indicating recessive disease. Targeted single-gene sequencing and gene panels (next-generation sequencing — NGS): disease-specific panels for cancer predisposition, cardiomyopathy, hearing loss, retinal dystrophies, neurodevelopmental disorders, and others — higher diagnostic yield than sequential single-gene testing at lower cost. Whole exome sequencing (WES): sequences all protein-coding exons (~1–2% of the genome); diagnostic yield 25–40% in undiagnosed rare disease following negative targeted testing; the dominant platform for undiagnosed disease programmes. Whole genome sequencing (WGS): sequences all approximately 3 billion base pairs; detects non-coding regulatory variants and structural variants missed by WES; yield approximately 5–10% higher than WES; increasing NHS and insurance coverage. Biochemical genetics: enzyme assays (for lysosomal storage disorders, fatty acid oxidation disorders) and metabolite measurement (plasma amino acids, urine organic acids, acylcarnitine profile) for suspected metabolic disorders. Functional assays (RNA sequencing, protein studies) resolve variants of uncertain significance (VUS).

Genetic counselling itself does not treat genetic disorders but is the foundation for informed, evidence-based management of individuals with or at risk for genetic conditions. Following genetic evaluation, the clinical pathway depends on the identified diagnosis and variant: For hereditary cancer syndromes: BRCA1/2 pathogenic variants — enhanced breast surveillance (annual MRI mammography from age 25; mammography from age 30), risk-reducing bilateral salpingo-oophorectomy (reduces ovarian cancer risk by over 95% and breast cancer risk by 50% in premenopausal women; discussed from age 35–40), and optional risk-reducing bilateral mastectomy (reduces breast cancer risk by over 90%) following completion of family-building; chemoprevention with tamoxifen or anastrozole (reduces contralateral risk by 40%). Lynch syndrome — intensive colonoscopic surveillance (every 1–2 years from age 20–25), prophylactic hysterectomy and bilateral salpingo-oophorectomy considered in women (reduces endometrial and ovarian cancer risk), aspirin chemoprevention (CAPP2 trial — 600 mg/day for 2 years reduced Lynch syndrome cancer incidence by 50% in 10-year follow-up). For reproductive decision-making: carriers of autosomal recessive conditions considering pregnancy — preimplantation genetic testing for monogenic disorders (PGT-M) via IVF allows biopsy and testing of embryos before uterine transfer, selecting unaffected embryos; prenatal diagnosis by chorionic villus sampling (CVS — 11–14 weeks) or amniocentesis (16–20 weeks) allows fetal diagnosis and continuation/termination decision-making; gamete donation (donor sperm or egg from an unaffected donor) or adoption are alternatives. For presymptomatic testing in adults at risk of late-onset conditions (Huntington's disease, familial cardiomyopathy, inherited cancer syndromes): comprehensive pre-test and post-test counselling addressing psychological readiness, implications of positive and negative results, impact on insurance (particularly relevant in countries without universal coverage), and support resources is mandatory before and after genetic testing.

Genetic counselling itself carries no medical risks but has important psychological implications. Receiving news of a pathogenic genetic variant can cause anxiety, depression, survivor guilt in unaffected family members, relationship strain, and difficult reproductive decisions. Variants of uncertain significance (VUS) cause diagnostic uncertainty and anxiety without clear clinical guidance. Insurance discrimination (in countries without genetic non-discrimination laws) remains a concern for some patients. Cascade testing of family members reveals carrier status in relatives who may not have sought testing and may have complex emotional responses.

Genetic counselling enables prevention of genetic conditions in future generations through informed reproductive planning. Preimplantation genetic testing (PGT-M) during IVF cycles screens embryos before transfer to prevent transmission of serious single-gene disorders. Prenatal diagnosis (CVS, amniocentesis) provides information for pregnancy decisions. Carrier screening programs (offered to couples before or during pregnancy) identify at-risk couples for common autosomal recessive conditions including cystic fibrosis, spinal muscular atrophy, sickle cell disease, and thalassemia. Universal expanded carrier screening panels identify risk for hundreds of conditions simultaneously.

Consider seeking genetic counselling for: a personal or family history of a known or suspected hereditary condition (BRCA1/2 breast/ovarian cancer, Lynch syndrome colorectal cancer, Huntington's disease, familial hypercholesterolaemia, hereditary haemochromatosis, or other genetic disorders); a family member diagnosed with a condition that may have a hereditary component before age 50; having two or more close relatives with the same cancer type; a child born with a birth defect, developmental delay, or suspected genetic syndrome; personal or partner history of chromosomal abnormalities (trisomy 21, balanced translocation); recurrent pregnancy loss (3 or more miscarriages); ethnicity-associated risk (e.g. Ashkenazi Jewish heritage and BRCA/Gaucher/Tay-Sachs risk; sickle cell and thalassaemia in African, Middle Eastern, South Asian populations); or prior to assisted reproduction (IVF/IUI with known genetic risk). Genetic counsellors provide non-directive support for decision-making — referral through your GP or specialist is usually the first step.